Bleeding complications in patients with squamous cell carcinoma of the head and neck

Cristiana Bergamini MD | Robert L. Ferris MD | Jing Xie ScD
Gabriella Mariani MD | Muzammil Ali MD | William C. Holmes MD
Kevin Harrington MRCP | Amanda Psyrri MD | Stefano Cavalieri MD
Lisa Licitra MD

1Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
2Department of Otolaryngology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
3Department of Epidemiology, AstraZeneca, Gaithersburg, Maryland, USA
4Global Medicine Development, AstraZeneca, Cambridge, UK
5Global Medicine Development, AstraZeneca, Gaithersburg, Maryland, USA
6The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, UK
7Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
8Department of Oncology and Hemato-Oncology, University of Milan, Italy

Abstract
Hemorrhage in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) may be attributed to chemotherapy and local tumor irradiation. Evidence of the relationship between hemorrhage in R/M HNSCC and targeted therapies, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors, or immune checkpoint inhibitors, is limited. We aimed to identify epidemiological and clinical data related to the occurrence of hemorrhage in R/M HNSCC and to explore its relationship with various therapies. We describe information obtained from literature searches as well as data extracted from a commercial database and a database from the author's institution (Istituto Nazionale dei Tumori of Milan). Evidence suggests that most bleeding events in R/M HNSCC are minor. Clinical trial safety data do not identify a causal association between hemorrhage and anti-EGFR agents or immune checkpoint inhibitors. In contrast, anti-VEGF agents are associated with increased, and often severe/fatal, hemorrhagic complications.

[Correction added on 16 Jun 2021, after first online publication: A new affiliation has been included for Prof. Licitra after the initial publication.]
1 | INTRODUCTION

Each year, approximately 700,000 new cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed in adults globally, with 380,000 deaths, including more than 10,000 in the United States alone. HNSCC is a heterogeneous disease and can arise in multiple anatomical locations within the head and neck area, including the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx, and nasopharynx.

Hemorrhage is a frequent problem for patients with recurrent and/or metastatic (R/M) HNSCC and can occur as either acute catastrophic events, episodic major bleeds, or ongoing low-volume oozing. In addition to spontaneous tumor bleeding, chemotherapy and local tumor irradiation have been reported as causes of hemorrhage in R/M HNSCC. The chances of bleeding in recurrent disease can be high considering tissue sequelae following previous chemoradiotherapy (CRT), and prior chemotherapy, in particular, can contribute to hemorrhage secondary to chemotherapy-induced thrombocytopenia.

Free radicals can trigger thrombosis, obliterate the adventitial vasa vasorum, and cause adventitial fibrosis, premature atherosclerosis, and weakening of the carotid arterial wall. This can result in carotid artery rupture (carotid blowout syndrome [CBS]), which requires prompt diagnosis and intervention to avert a fatal outcome. Furthermore, high fractional and total radiotherapy doses may influence the risk of vascular mucosal damage especially in the repeat irradiation setting.

In addition to CRT, surgery has been implicated in causing hemorrhage in patients with R/M HNSCC. Pseudoaneurysms have been reported in patients up to 20 years after radical neck dissection and irradiation. In addition, stripping of the carotid sheath in association with neck dissection can compromise nutrition of the local tissue, rendering the carotid artery more vulnerable to CBS. The adoption of reconstructive techniques that use well-vascularized flaps has helped to reduce the risk of CBS following head and neck surgery.

Bacterial infections at surgical sites in the head and neck have been identified as a potential cause of vasa vasorum thrombosis and arterial wall injury. Surgical site infection also causes tissue necrosis and fistula formation. Patients with a pharyngocutaneous fistula are particularly at risk due to trypsin enzyme activity in saliva coming into contact with the arterial wall. Exposure to salivary enzymes may result in desiccation and digestion of the carotid artery wall, leaving it prone to rupture. In addition, direct tumor invasion and accompanying inflammation may play a role in weakening the arterial wall. In cases of acute hemorrhage associated with fistula and advanced necrosis, surgical ligation might be required, although, in most cases, endovascular techniques are now standard.

With the advent of promising targeted therapies for patients with HNSCC, the question arises as to whether the risk of hemorrhage will be as severe as that associated with palliative chemotherapy. A range of targeted therapies approved by the US Food and Drug Administration (FDA) and the European Medicines Agency are available for the treatment of R/M HNSCC, including epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab) and EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib, afatinib, and dacomitinib). The vascular endothelial growth factor (VEGF) antibody, bevacizumab, and VEGF receptor inhibitors (sorafenib, sunitinib, and vandetanib) are also being investigated as treatments for HNSCC. Currently, it is unclear whether a causal association exists between the use of these agents and the occurrence of hemorrhage in R/M HNSCC. More recently, immune checkpoint inhibitors (ICIs) have emerged as viable treatment options for R/M HNSCC, including the approved drugs pembrolizumab and nivolumab. Based on clinical trial data for these agents, and other ICIs under evaluation (durvalumab and tremelimumab), there is insufficient evidence to suggest that these agents significantly contribute to an increase in the incidence of hemorrhage in R/M HNSCC.

In this review, we provide real-world evidence on the occurrence of hemorrhage in patients with R/M HNSCC and present clinical trial data regarding a possible causal relationship between various treatments and bleeding events in patients with R/M HNSCC.

2 | DATA SOURCES

We describe relevant epidemiological and clinical data related to the occurrence of hemorrhage in patients with R/M HNSCC for a range of anticancer treatments. Information and qualitative data from the following sources...
were used: PubMed (1989–2019); the Truven MarketScan® Commercial Claims and Encounters database (2010–2015)25; and the Head & Neck Medical Oncology Department of the Istituto Nazionale dei Tumori of Milan database (1984–2016).26

2.1  Definition of hemorrhage

Hemorrhage is defined in the Introductory Guide for Standardised MedDRA Queries (SMQs) Version 22.0 as the escape of blood from vessels (“bleeding”). Small hemorrhages are classified according to size as petechiae (very small), purpura (up to 1 cm), and ecchymoses (larger). A large accumulation of blood within a tissue is called a hematoma. The Common Terminology Criteria for Adverse Events (CTCAE) grades hemorrhage as follows: grade 1 does not require any intervention, grade 2 requires medical intervention, and grade 3 requires surgical intervention. For the purpose of the studies described in this review, all hemorrhagic events were considered as CTCAE grade ≥2 unless specified otherwise.

2.2  PubMed

For the purposes of this narrative review, PubMed search criteria were limited to R/M information and risk factors for hemorrhage in patients with advanced cancers, particularly those with R/M HNSCC. The focus on R/M was due to patients with R/M HNSCC being more prone to hemorrhage.3 Only papers published in English were considered. The search strategy used key words and appropriate medical subject headings, which included combinations of “bleeding,” “hemorrhage,” “recurrent,” “metastatic,” “head and neck,” “CRT,” “radiation therapy,” “surgery,” “angiogenic therapy,” “anti-VEGF,” “anti-EGFR,” “checkpoint inhibitors,” and “immunotherapies.” The Google search engine was also employed, applying combinations of the same search terms.

2.3  The Truven MarketScan database

For the purposes of understanding epidemiologic data for patients in the United States, the Truven MarketScan database (established 1995) is a medical and drug insurance claims database of approximately 174 million unique de-identified patients that includes active employees, early retirees, COBRA continuers, and their dependents insured by employer-sponsored health plans. It is composed of administrative claims data of patients with commercial insurance, and additional separate data files include patients covered by Medicare supplemental insurance. The Truven MarketScan Commercial Claims and Encounters database for the years 2010–2015 was used as a data source for the evaluation of hemorrhagic events in patients with head and neck cancers. The head and neck cancer study population included patients with an initial medical encounter for cancer of the pharynx, larynx, or oral cavity (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 140–149 and 161) indicative of a diagnosis between 2010 and 2015. Patients with tumors of uncertain origin and benign neoplasms were excluded. The population was further stratified based on those who received cancer chemotherapy using Anatomical Therapeutic Chemical codes corresponding to antineoplastic agents and who had received radiation therapy on the basis of procedure (Current Procedural Terminology) codes.

Data analyses were performed to calculate the incidence and event rates for hemorrhage. A hemorrhage event was defined on the basis of the first listed ICD-9-CM diagnostic code provided from patients’ medical encounters identified by the translation of 449 preferred terms (MedDRA Version 22.0) included in the SMQ for hemorrhage. In addition, a subset of 77 preferred terms from the hemorrhage SMQ localized in the area of head and neck was defined.

Assessment of the effect of risk factors for hemorrhage was limited to an assessment of history of prior hemorrhage in the 3-month period before first treatment. Subset analyses were performed to evaluate the subsequent rates of hemorrhagic events in patients stratified based on presence or absence of prior history of hemorrhage in the 3 months before initiating palliative radiation or chemotherapy for their respective cancers. Outcomes were reported as incidence rates per 100 patients (representing the proportion of patients experiencing a hemorrhagic event) and based upon incidence densities (reported as event rates per 100 patient-years).

The HNSCC study population in the Truven dataset included patients with an initial medical encounter for cancer of the pharynx, larynx, or oral cavity indicative of a diagnosis made between 2010 and 2015. Analysis of hemorrhagic events was conducted both in patients eligible for commercial insurance (aged <65 years) and in those eligible for Medicare with supplemental insurance (aged ≥65 years).

2.4  Istituto Nazionale dei Tumori of Milan database

A total of 259 consecutive patients with R/M HNSCC, from whom we had complete data for the analysis of hemorrhagic events, were seen between 1984 and 2016 at the Head and Neck Medical Oncology Department of the
Istituto Nazionale dei Tumori of Milan. The incidence rates of bleeding in recurrent HNSCC, specific bleeding risk factors, and cause of death were assessed and resulting life expectancy and overall survival in patients with bleeding recurrence were evaluated.

The search included patients who were aged ≥18 years at diagnosis, with histologically confirmed advanced R/M HNSCC of the oral cavity, oropharynx, hypopharynx, larynx, or unknown primary site that was not amenable to curative surgery or radiotherapy, and with measurable disease (≥10 mm in the longest diameter). The search was further narrowed to patients with tumor progression or recurrence within 6 months of the last dose of platinum therapy in the adjuvant (i.e., with radiation after surgery) or primary (i.e., with radiation) setting (first population) or recurrent or metastatic setting (second population). Patients with primary anatomic location in the head and neck not specified in the inclusion criteria, nonsquamous histologies, and other sites (e.g., nasopharynx or salivary glands or paranasal sinuses) were excluded from the analysis.

Recurrence was defined according to date of relapse, time to relapse, type of recurrence (local, nodal, soft tissue, trachea, parastomal, lung, or metastasis), size of recurrence, dose of radiotherapy on recurrence site, concomitant local infection, number of antibiotic therapies (≤3 or >4 lines), and data on hemorrhagic events. Systemic treatment at recurrence was defined by the number of chemotherapy lines at recurrence or metastatic disease. Hemorrhage characteristics during recurrence were assessed according to site, date of first hemorrhage, and type of hemorrhage (minor, major, or fatal). Minor hemorrhage was estimated as bright red blood of half a teaspoon or more per episode of coughing (~5 mL). Major hemorrhage was defined as fatal, life-threatening, symptomatic, causing a drop in hemoglobin of 20 g/L or more, leading to transfusion of two or more units of whole blood or red cells or about 200–240 mL, or about 1 cup, in 24 h. Finally, disease evolution was date of death (or last contact with the patient) and the cause of death (hemorrhage, progressive disease, toxicity, infection, or other). The conduct of the retrospective study was approved by the institutional Ethical Committee on 26th April 2017 (local study identifier INT 77-17). Approval for patient consent waiver was obtained through the Ethical Committee.

3 | HEMORRHAGIC EVENTS IN HNSCC: REAL-WORLD EVIDENCE

3.1 | The Truven MarketScan database

In the commercially insured population (aged <65 years) with R/M HNSCC who received both radiation therapy and systemic chemotherapy, the incidence rate for a hemorrhage event was 36.7%, and the event rate was 33.4 per 100 person-years. The incidence rate for the subset of 77 preferred terms specific to hemorrhage in HNSCC was 27.6%, and the event rate was 22.7 events per 100 patient-years. When these analyses were performed after adjusting for the experience of a hemorrhagic event in the 3-month period before the most recent treatment, the incidence rate for a hemorrhagic event was 50.7%, and the event rate was 63.4 per 100 person-years. The incidence rate for the set of preferred terms related to hemorrhage in HNSCC was 44.3%, and the event rate was 50.5 events per 100 patient-years.

In the supplemental Medicare coverage population (aged ≥65 years) with HNSCC who received both radiation therapy and systemic chemotherapy, the incidence rate for a hemorrhagic event, based upon hemorrhage SMQ was 53.4%, and the event rate for the hemorrhage SMQ was 52.1 per 100 patient-years. The incidence rate for the set of preferred terms was 38.4%, and the event rate for the preferred terms related to hemorrhage in HNSCC was calculated as 31.0 events per 100 patient-years.

The present analysis of the Truven MarketScan database suggests that patients with HNSCC who had received radiation or chemotherapy have a higher likelihood of hemorrhage given a history of hemorrhage prior to first treatment for recurrent disease than no prior history. Furthermore, these analyses suggest that this increased risk of bleeding given a prior history of bleeding may be worse in patients ≥65 years than in those <65 years of age.

3.2 | Istituto Nazionale dei Tumori of Milan database

In the Head & Neck Medical Oncology Department at the Istituto Nazionale dei Tumori of Milan, hemorrhage events were analyzed from 259 consecutive patients with R/M HNSCC treated between 1984 and 2016, according to the presence or absence of hemorrhage from the cancer lesion itself in the context of R/M disease. The median follow-up time was 24 months (range, 1–303).

Patient demographics and disease characteristics of the 259 patients are listed in Table 1. In total, 110 of 259 patients (42%) with R/M HNSCC experienced at least one hemorrhagic event, of which 104 (95%) experienced hemorrhage in the head and neck (Table 2). Five patients (5%) had hemorrhage in the lung and one patient (1%) had hemorrhage in a site described as “other.” Most hemorrhagic events occurred during first-line therapy, and most patients were receiving chemotherapy during the first hemorrhagic event (37, 34%) followed by anti-EGFR antibodies with or without chemotherapy (29, 26%) and immunotherapy (12, 11%)
The proportion of patients who had at least one episode of bleeding versus the proportion without an episode of bleeding were similar in terms of the number of systemic therapies given for recurrence and the types of treatment (Table 3).

The findings from the present database analysis suggest that most bleeding events were minor and not linked to treatment, although cautious interpretation is warranted given the size of the patient population. The data analyses dealt mostly with patients previously treated with chemoradiation and suggest that its involvement in hemorrhagic events may be limited. In addition to chemoradiation, additional tentative etiologies of hemorrhage are under scrutiny, including the biology of the disease (e.g., infection with high-risk human papillomaviruses [HPVs]) and a range of emerging therapies such as antiangiogenic agents, anti-EGFR drugs, and immunotherapies.

(Table 2). The proportion of patients who had at least one episode of bleeding versus the proportion without an episode of bleeding were similar in terms of the number of systemic therapies given for recurrence and the types of treatment (Table 3).

The findings from the present database analysis suggest that most bleeding events were minor and not linked to treatment, although cautious interpretation is warranted given the size of the patient population. The data analyses dealt mostly with patients previously treated with chemoradiation and suggest that its involvement in hemorrhagic events may be limited. In addition to chemoradiation, additional tentative etiologies of hemorrhage are under scrutiny, including the biology of the disease (e.g., infection with high-risk human papillomaviruses [HPVs]) and a range of emerging therapies such as antiangiogenic agents, anti-EGFR drugs, and immunotherapies.
THERAPIES FOR HNSCC AND RISK OF HEMORRHAGE

4.1 | Anti-EGFR therapies

EGFR is overexpressed in the majority of HNSCC cases and is a well-recognized therapeutic target. Clinical trials have therefore examined the efficacy and safety of targeted anti-EGFR agents such as cetuximab. However, based on available data, it remains unclear whether a causal association exists between the use of cetuximab-based treatment regimens and occurrence of hemorrhage.

In a multinational randomized trial of high-dose radiotherapy plus cetuximab versus high-dose radiotherapy alone (424 patients with stage III or IV nonmetastatic, measurable HNSCC of the oropharynx, hypopharynx, or larynx), no hemorrhagic adverse events (AEs) were reported in either treatment arm. In an open-label, uncontrolled multicenter phase II study of single-agent cetuximab in patients with R/M HNSCC who experienced disease progression on platinum-based therapy, the most common cetuximab-related AEs were skin reactions. There was one treatment-related death due to an uncommon infusion-related reaction, but there were no reports of hemorrhage. Similarly, hemorrhage was not described among 117 evaluable patients in a randomized trial comparing cisplatin–cetuximab with cisplatin–placebo. However, the study reported grade 1 or 2 hemorrhage events occurred.

In a phase III randomized controlled trial comparing patients treated with cetuximab plus platinum–fluorouracil (n = 222) versus patients treated with platinum–fluorouracil alone (n = 220), 1.4% of patients in the cetuximab arm developed grade 3 or 4 tumor hemorrhagic events compared with 2.8% in the platinum–fluorouracil arm. The AE profile in the chemotherapy alone group was

| Patients not bleeding (n = 149) | Patients bleeding (n = 110) | Total patients (N = 259) |
|---------------------------------|-----------------------------|-------------------------|
| **Systemic therapy at recurrence, n (%)** | | |
| Yes                             | 133 (89)                    | 104 (95)                | 237 (92) |
| No                              | 16 (11)                     | 6 (5)                   | 22 (8) |
| Number of systemic therapies for recurrence, median (range) | 2 (0–7) | 2 (0–8) | 2 (0–8) |

| Total number of lines of systemic therapy for recurrence, n (%) | | |
|---------------------------------------------------------------|-------------|-------------|
| 0                                                             | 16 (11)     | 6 (5)       | 22 (8) |
| 1                                                             | 52 (35)     | 43 (39)     | 95 (37) |
| 2                                                             | 48 (32)     | 33 (30)     | 81 (31) |
| ≥ 3                                                           | 33 (22)     | 28 (25)     | 61 (24) |

| Line and type of treatment, n (%) | | |
|---------------------------------|-------------|-------------|
| **First line**                 | 133 (89)    | 104 (95)    | 237 (92) |
| Anti-EGFR ± chemo               | 88 (59)     | 75 (68)     | 163 (63) |
| Chemotherapy                    | 36 (24)     | 21 (18)     | 57 (22) |
| Immunotherapy                   | 9 (6)       | 8 (7)       | 17 (7) |
| **Second line**                | 81 (54)     | 61 (55)     | 142 (55) |
| Anti-EGFR ± chemo               | 6 (4)       | 10 (9)      | 16 (6) |
| Chemotherapy                    | 59 (39)     | 41 (37)     | 100 (39) |
| Immunotherapy                   | 16 (11)     | 10 (9)      | 26 (10) |
| **Third line**                 | 33 (22)     | 28 (25)     | 61 (24) |
| Anti-EGFR ± chemo               | 3 (2)       | 1 (1)       | 4 (1) |
| Chemotherapy                    | 28 (18)     | 25 (23)     | 53 (20) |
| Immunotherapy                   | 2 (1)       | 2 (1)       | 4 (1) |

Note: Anti-EGFR therapy/chemotherapy: carboplatin + cetuximab; carboplatin + cetuximab + 5-FU; cisplatin + cetuximab; cisplatin + cetuximab + 5FU; cisplatin + cetuximab + taxane. Immunotherapy: nivolumab; nivolumab + lirilumab; pembrolizumab; tremelimumab + durvalumab.
Abbreviations: EGFR, epidermal growth factor receptor; 5-FU, 5-fluorouracil; HNSCC, head and neck squamous cell carcinoma.
Source: “Bleeding in recurrent and/or metastatic patients with head and neck squamous cell carcinoma: the experience at the Istituto Nazionale Tumori of Milan.”
considered typical for a platinum–fluorouracil combination. The main grade 3 or 4 AEs, including tumor hemorrhage, were assessed by the investigators as being consistent with the safety profile of cetuximab.

Cripps et al. reviewed the evidence for inclusion of anti-EGFR therapies in guidelines for the treatment of HNSCC. Of note, discussion of the development of the EGFR therapies in guidelines for the treatment of HNSCC. Consistent with the safety profile of cetuximab.

Several studies investigating angiogenesis inhibitors have reported treatment-related bleeding complications (Table 4). Seiwert et al. performed a phase I study evaluating the combination of bevacizumab, 5-fluorouracil, hydroxyurea, and concomitant radiotherapy for poor-prognosis patients with HNSCC. Of 43 treated patients, two fatal hemorrhages were reported, one esophageal and one carotid blowout. The latter was thought to be secondary to tumor invasion of the carotid artery and was not evident at baseline. In another study, Cohen et al. investigated the combination of erlotinib and bevacizumab in 56 patients with R/M HNSCC. Three patients (5%) experienced serious hemorrhagic events. Of four toxic effects that led to discontinuation, serious hemorrhagic events were responsible for two. One serious hemorrhagic event was fatal and determined to be of laryngeal origin; however, this did not occur at a site of active disease. The other hemorrhagic event occurred at a site of disease involvement in the floor of the mouth. Importantly, all three hemorrhagic events were associated with prior radiotherapy to the site.

A recent phase III randomized trial evaluated the efficacy and safety of chemotherapies with or without bevacizumab in patients with R/M HNSCC. The addition of bevacizumab to chemotherapy did not improve overall survival but improved the response rate and progression-free survival with increased toxicities. A higher rate of treatment-related grade 3–5 hemorrhage events (6.7% vs. 0.5%; p < 0.001) was observed with the bevacizumab/chemotherapy combination versus chemotherapy alone. In a single-arm, phase II trial of 27 patients treated with sorafenib, one patient experienced a fatal nasopharyngeal hemorrhage, although the death was considered to be unrelated to treatment. In several other studies examining different antiangiogenesis therapies, hemorrhagic events were not documented; this means that either hemorrhagic events did not occur or, if they occurred, they were beneath the threshold to be reported. In general, anti-VEGF-based therapies are more commonly associated with hemorrhage.

4.2 Angiogenesis inhibitors

Antiangiogenic drugs, specifically anti-VEGF agents, are associated with increased and often severe incidence of hemorrhage complications. Management of bleeding in patients treated with anti-VEGF agents can be challenging as this complication is attributable, at least in part, to the efficacy of the drug.

Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is associated with an increased risk of severe or fatal hemorrhage compared with chemotherapy. Several studies investigating angiogenesis inhibitor-based combination therapies in patients with R/M HNSCC have reported treatment-related bleeding complications (Table 4). Seiwert et al. performed a phase I study evaluating the combination of bevacizumab, 5-fluorouracil, hydroxyurea, and concomitant radiotherapy for poor-prognosis patients with HNSCC. Of 43 treated patients, two fatal hemorrhages were reported, one esophageal and one carotid blowout. The latter was thought to be secondary to tumor invasion of the carotid artery and was not evident at baseline. In another study, Cohen et al. investigated the combination of erlotinib and bevacizumab in 56 patients with R/M HNSCC. Three patients (5%) experienced serious hemorrhagic events. Of four toxic effects that led to discontinuation, serious hemorrhagic events were responsible for two. One serious hemorrhagic event was fatal and determined to be of laryngeal origin; however, this did not occur at a site of active disease. The other hemorrhagic event occurred at a site of disease involvement in the floor of the mouth. Importantly, all three hemorrhagic events were associated with prior radiotherapy to the site.

A recent phase III randomized trial evaluated the efficacy and safety of chemotherapies with or without bevacizumab in patients with R/M HNSCC. The addition of bevacizumab to chemotherapy did not improve overall survival but improved the response rate and progression-free survival with increased toxicities. A higher rate of treatment-related grade 3–5 hemorrhage events (6.7% vs. 0.5%; p < 0.001) was observed with the bevacizumab/chemotherapy combination versus chemotherapy alone. In a single-arm, phase II trial of 27 patients treated with sorafenib, one patient experienced a fatal nasopharyngeal hemorrhage, although the death was considered to be unrelated to treatment. In several other studies examining different antiangiogenesis therapies, hemorrhagic events were not documented; this means that either hemorrhagic events did not occur or, if they occurred, they were beneath the threshold to be reported. In general, anti-VEGF-based therapies are more commonly associated with hemorrhage.

4.3 Immunoitherapy: Nonimmune checkpoint inhibitors

Local and systemic immunotherapy modalities may lead to inflammation; therefore, local tumor vaccination and systemic immune stimulant clinical trial reports in HNSCC were reviewed. A phase I/II study evaluating JS1/34.5/-47/-GM-CSF, an oncolytic herpes simplex type 1 virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF), in combination with CRT in patients with HNSCC reported injection site hemorrhage in two (12%) patients. Hemorrhage did not result in any deaths or delay ongoing radiotherapy. A phase I study evaluated the safety, tolerability, and tumor response of VB4-845, a recombinant fusion protein that targets...
4.4 Immunotherapy: ICIs

Recent advances in cancer immunotherapy are notable for the introduction of ICIs. These agents inhibit negative regulatory components of the immune response, such as the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein-1 (PD-1) and its ligand, programmed cell death ligand-1 (PD-L1), which lead to enhanced T cell action against cancer cells. The incidences of hemorrhage events in clinical studies of ICIs are summarized in Table 4.

In 2016, two PD-1 inhibitors, nivolumab and pembrolizumab, were approved for the treatment of patients with R/M HNSCC who experience disease progression after platinum-based therapy. Furthermore, on June 10, 2019, the US FDA approved pembrolizumab for the first-line treatment of patients with R/M HNSCC when used in combination with platinum and...
fluorouracil (all patients) or as a single agent (for patients whose tumors express PD-L1 based on a combined positive score of ≥1 as determined by an FDA-approved test). Hemorrhage is not included as a warning or precaution in the prescribing information for either nivolumab or pembrolizumab.

Recently, data have been published from clinical trials investigating safety and efficacy of the checkpoint inhibitor durvalumab, both alone, and in combination with the anti-CTLA-4 agent tremelimumab. In the phase II CONDOR study, patients with PD-L1-low/negative R/M HNSCC received durvalumab with or without tremelimumab. In the combination arm, bleeding events included hemorrhage in one (0.8%) patient, epistaxis in three (2.3%) patients, and hemoptysis in five (3.8%) patients. In the durvalumab arm, epistaxis and hemoptysis were each reported in one (1.5%) patient, whereas in the tremelimumab arm a single patient (1.5%) experienced hemoptysis. Among the 11 reported bleeding events, two in the combination arm were considered to be related to treatment, including one patient with epistaxis and one with hemoptysis (Tables 5 and 6). In the phase II HAWK study, patients with R/M HNSCC and ≥25% tumor cell PD-L1 expression who had progressed on platinum-based chemotherapy received durvalumab monotherapy. Two patients (1.8%) experienced treatment-related hemorrhage (one patient with mouth hemorrhage and one patient with wound hemorrhage; Tables 5 and 6).

In the phase III EAGLE study, patients with R/M HNSCC received durvalumab plus tremelimumab or durvalumab monotherapy (Tables 5 and 6). A review of all bleeding events within the hemorrhage SMQ revealed that the incidence was low and within the range reported in the published literature for patients with advanced cancer. Most of the hemorrhage SMQ serious AEs (SAEs) were not considered to be related to study drug by the investigators and there were no clear trends across groups in the hemorrhage SMQ SAEs that led to death. During the study, 103 patients experienced 119 hemorrhage SMQ AEs; of these, 8 (3.4%) were thought to be related to study treatment in the durvalumab arm, 11 (4.5%) in the durvalumab plus tremelimumab arm, and 9 (3.8%) in the standard-of-care (SoC) arm (Table 6). There were no apparent differences across the treatment groups in proportions of patients experiencing hemorrhage SMQ AEs. However, in the durvalumab plus tremelimumab group, there were two patients who experienced treatment-related hemorrhage SMQ AEs of CTCAE grade 3 or 4 where there were none in the durvalumab or SoC arms. SAEs that were considered related to treatment were reported more frequently in the durvalumab (n = 2) and durvalumab plus tremelimumab (n = 2) groups than SoC (n = 0). Hemorrhage SMQ AEs considered to be related to treatment and leading to discontinuation of study treatment occurred in one patient in the durvalumab arm and no patients in the other arms. Overall, one patient in the durvalumab arm had a fatal treatment-related hemorrhage SMQ AE. Ultimately, an association between durvalumab or durvalumab plus tremelimumab and hemorrhage-related AEs was not identified.

5 | SUMMARY

We analyzed and reviewed relevant epidemiologic and clinical data in patients with R/M HNSCC in order to further our understanding of the occurrence of hemorrhage in this tumor type. The availability of several sources of data, including the Truven MarketScan Commercial Claims and Encounters Database (2010–2015) and the Istituto Nazionale dei Tumori of Milan database (1984–2016), have allowed us to conduct a comprehensive review of bleeding events in R/M HNSCC. Several possible causes of hemorrhage in R/M HNSCC have been examined, including disease-related characteristics, traditional therapies (chemotherapy, radiotherapy), and emerging therapies (antiangiogenic and anti-EGFR agents, immunotherapies). The real-world findings from the Istituto Nazionale dei Tumori of Milan database suggest that most bleeding events were minor and initial analyses did not indicate an association with treatment. However, interpretation of these data should be approached with caution due to the small population of patients analyzed.

Although systemic chemotherapy (especially when delivered intra-arterially) and local tumor irradiation are possible causes of intractable hemorrhage associated with head and neck neoplasms, real-world evidence from the Truven MarketScan Commercial Claims and Encounters database possibly cautions against an assumption that chemoradiation therapy is responsible for hemorrhagic events. These analyses suggest that individuals with HNSCC who had received radiation therapy and chemotherapy, with a history of hemorrhagic events in the 3 months prior to first treatment, experienced higher subsequent rates of hemorrhage than those with no previous history of hemorrhage. Although not providing a mechanistic explanation for the increased hemorrhagic risk, these data nevertheless indicate that patient and/or disease-related factors drive hemorrhagic events in at-risk individuals undergoing chemoradiation. While confirmation is required, the present analyses suggest that age may play a role, as patients ≥65 years of age had higher
| Reference | Study phase/design | N  | Agent(s) | Tumor | Rate of hemorrhage/bleeding |
|-----------|--------------------|----|----------|-------|-----------------------------|
| Yervoy® US PI | NA | NA | Ipilimumab | Melanoma | Hemorrhagic events not described |
| Hodi et al. | Randomized phase III trial in patients with unresectable stage III or IV melanoma | 676 | Ipilimumab <br>Ipilimumab + gp100 gp100 | Melanoma | Hemorrhagic events not described |
| Larkin et al. | Randomized phase III trial in previously untreated patients with unresectable stage III or IV melanoma | 945 | Nivolumab <br>Nivolumab + ipilimumab | Melanoma | Hemorrhagic events not described |
| Eggermont et al. | Randomized phase III trial in patients with who had undergone complete resection of stage III melanoma | 951 | Ipilimumab <br>Placebo | Melanoma | Hemorrhagic events not described |
| Opdvo® US PI | NA | NA | Nivolumab | Melanoma | Hemorrhagic events not described |
| Postow et al. | Randomized phase I dose-escalation study in patients with treatment naïve metastatic melanoma | 142 | Nivolumab <br>Nivolumab + ipilimumab <br>Nivolumab + placebo | Melanoma | Hemorrhagic events not described |
| Ansell et al. | Phase I study of patients with relapsed or refractory HL | 23 | Nivolumab | HL | Hemorrhagic events not described |
| Gettinger et al. | Phase I study of patients with heavily pretreated NSCLC | 129 | Nivolumab | NSCLC | Hemorrhagic events not described |
| Ferris et al. | Randomized phase III study of patients with R/M HNSCC | 361 | Nivolumab | HNSCC | Hemorrhagic events not described |
| Keytruda® US PI | NA | NA | Pembrolizumab | Melanoma | Hemorrhagic events not described |
| Topalian et al. | Phase I study of patients with advanced melanoma, NSCLC, castration-resistant prostate cancer, or renal-cell or colorectal cancer | 296 | Pembrolizumab | Advanced solid tumors | Hemorrhagic events not described |
| Armand et al. | Phase I study of patients with relapsed or refractory HL after treatment with brentuximab | 31 | Pembrolizumab | HL | Hemorrhagic events not described |
| Chow et al. | Phase Ib study in patients with R/M HNSCC | 132 | Pembrolizumab | HNSCC | Hemorrhagic events not described |
| Reference                  | Study phase/design                                                                 | N    | Agent(s)          | Tumor                  | Rate of hemorrhage/bleeding                                      |
|----------------------------|-------------------------------------------------------------------------------------|------|-------------------|------------------------|----------------------------------------------------------------|
| Seiwert et al.²⁰           | Phase Ib study of patients with R/M HNSCC                                            | 104  | Pembrolizumab     | HNSCC                  | Hemorrhagic events not described                                |
| Bauml et al.¹⁴             | Phase II study of patients with R/M HNSCC                                            | 171  | Pembrolizumab     | HNSCC                  | Hemorrhagic events not described                                |
| Tecentriq® US-Pf²⁴          | NA                                                                                  | NA   | Atezolizumab      | UC                     | Hemorrhagic events not described                                |
| Calabro et al.²¹           | Phase II study of previously treated patients with unresectable malignant mesothelioma | 29   | Tremelimumab      | Malignant mesothelioma | Hemorrhagic events not described                                |
| Siu et al.²²               | Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial | 65   | Durvalumab        | HNSCC                  | Minor bleeding events; two patients (1.5%) in combination arm with treatment-related bleeding |
| Zandberg et al.²³          | Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with 25% tumor cell PD-L1 expression who have progressed on platinum-based chemotherapy | 112  | Durvalumab        | HNSCC                  | Minor bleeding events; two patients (1.8%) with treatment-related bleeding |
| Ferris et al.²⁴            | Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (EAGLE): a randomized, open-label phase III study | 237  | Durvalumab        | HNSCC                  | Minor treatment-related bleeding events 8 (3.4%) patients (durvalumab) 11 (4.5%) patients (durvalumab + tremelimumab) 9 (3.8%) patients (SoC) |

Note: Trials determined from PubMed search ranging from 1989 to 2019 (search criteria described in section 2).

Abbreviations: HL, Hodgkin’s lymphoma; NA, not applicable; NSCLC, non-small cell lung cancer; PI, prescribing information; RCC, renal cell carcinoma; SoC, standard of care; UC, urothelial carcinoma; US, United States.
rates of hemorrhage than those <65 years of age. The relationship between primary tumor location and occurrence of bleeding events is unclear from our analyses, although most patients in our study population had locally advanced disease. There were too few patients with HPV-positive oropharyngeal cancer to determine if HPV infection has an impact on risk of bleeding in R/M HNSCC. While half of the patients in our study population had received surgery, it is unclear if this impacted the carotid artery and thus the risk of bleeding with systemic therapy in at least some patients.

Clinical trials have examined the efficacy and safety of targeted anti-EGFR agents in patients with R/M HNSCC; however, based on available data, a causal association between these treatment regimens and occurrence of hemorrhage cannot be confirmed. In addition, local and systemic immune stimulators do not appear to be associated with increased frequency of tumor hemorrhage in this patient population. In contrast, antiangiogenic drugs, specifically anti-VEGF agents, are associated with increased and often severe incidence of hemorrhagic complications, based on a review of the current literature. Stronger effort needs to be made to mitigate hemorrhagic risk in this population and more research needs to be conducted to identify pertinent risk factors.

No evidence to date was identified to suggest a class-effect of checkpoint inhibitors in risk of hemorrhage when treating R/M HNSCC with single-agent or combination checkpoint inhibitor therapy. With the FDA-approved PD-1 inhibitors nivolumab and pembrolizumab not listing hemorrhage-associated side effects in R/M HNSCC, and clinical trials for durvalumab and tremelimumab finding no evidence to support a causal relationship with bleeding-related AEs, checkpoint inhibitors so far present a viable option for treating R/M HNSCC without an increased hemorrhagic risk.

In conclusion, hemorrhagic episodes can be a frequent problem in patients with advanced cancer including those with R/M HNSCC, ranging from low-grade oozing to major episodic and catastrophic bleeding. Hemorrhage can be caused by the cancer itself and may also be related to antitumor treatments such as prior radiation therapy or chemotherapy. Hemorrhage can be further exacerbated by addition of anti-VEGF agents, nonsteroidal anti-inflammatory drugs, and anticoagulants. In patients at high risk of bleeding including those with a prior hemorrhage, treatment goals need to be aligned with this risk. Ultimately, the use of therapies that have maximal efficacy and minimal or no hemorrhage-related effects will be more desirable when selecting therapeutic options for patients with R/M HNSCC.

### TABLE 6  Bleeding incidence in the HAWK, CONDOR, and EAGLE trials

| AE, n (%) | **HAWK**<sup>23</sup> | **CONDOR**<sup>22</sup> | **EAGLE**<sup>24</sup> |
|---|---|---|---|
| D (N = 112) | D + T (N = 133) | D (N = 65) | D + T (N = 246) | D (N = 237) | SoC (N = 240) |
| All bleeding AEs | 9 (6.8) | 2 (3.1) | 36 (14.6) | 37 (15.6) | 30 (12.5) |
| Treatment-related bleeding AE | 2 (1.8) | 2 (1.5) | 0 | 11 (4.5) | 8 (3.4) | 9 (3.8) |
| Tumor hemorrhage | 0 | 0 | 0 | 1 (0.4) | 1 (0.4) | 1 (0.4) |
| Lymph node hemorrhage | 0 | 0 | 0 | 0 | 1 (0.4) | 0 |
| Hematoma | 0 | 0 | 0 | 0 | 0 | 1 (0.4) |
| Hemorrhage | 0 | 0 | 0 | 0 | 1 (0.4) | 0 |
| Hemoptysis | 0 | 1 (0.8) | 0 | 3 (1.2) | 4 (1.7) | 0 |
| Epistaxis | 0 | 1 (0.8) | 0 | 1 (0.4) | 0 | 5 (2.1) |
| Pharyngeal hemorrhage | 0 | 0 | 0 | 1 (0.4) | 0 | 0 |
| Mouth hemorrhage | 1 (0.9) | 0 | 0 | 2 (0.8) | 1 (0.4) | 1 (0.4) |
| Upper gastrointestinal hemorrhage | 0 | 0 | 0 | 1 (0.4) | 0 | 0 |
| Palpable purpura | 0 | 0 | 0 | 1 (0.4) | 0 | 0 |
| Petechiae | 0 | 0 | 0 | 1 (0.4) | 0 | 0 |
| Purpura | 0 | 0 | 0 | 1 (0.4) | 0 | 0 |
| Hematuria | 0 | 0 | 0 | 0 | 1 (0.4) | 0 |
| Wound hemorrhage | 1 (0.9) | 0 | 0 | 0 | 0 | 0 |

Abbreviations: AE, adverse event; D, durvalumab; SoC, standard of care; T, tremelimumab.
ACKNOWLEDGMENTS
Medical writing and editorial support, in accordance with Good Publication Practices, were provided by Ward A. Pedersen of Parexel (Hackensack, NJ) and were funded by AstraZeneca. The collection, analysis, and interpretation of the data were conducted by the academic authors in collaboration with the sponsor (AstraZeneca).

CONFLICT OF INTEREST
Robert L. Ferris. Consulting or Advisory Role: Aduro Bio-tech Inc., Bristol Myers Squibb, Merck, Pfizer, EMD Serono, Numab Therapeutics AG, Macrogenics, Novasenta (Stock as well). Research Funding: Bristol Myers Squibb, AstraZeneca/MedImmune, Merck, Tesaro, Novasenta. Jing Xie, Gabriella Mariani, and Muzammil Ali are employed by AstraZeneca. William C. Holmes was employed by AstraZeneca and he is currently employed by GlaxoSmithKline. Kevin Harrington: Consulting or Advisory Role: Arch Oncology, AstraZeneca/MedImmune, Bristol Myers Squibb, Boehringer-Ingelheim, Merck-Serono, Merck-Sharp-Dohme, Nanobiotix, Oncolys, Pfizer, Replimune, Vyriad. Research Funding: AstraZeneca/MedImmune, Boehringer-Ingelheim, Merck-Sharp-Dohme, Replimune, The Royal Marsden Hospital/The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre. Amanda Psyrri: Honoraria: Merck Serono, Roche, BMS, MSD Oncology, Genesis Pharmaceuticals, Bayer, Rakuten, AstraZeneca, Pfizer. Consulting or Advisory Role: AstraZeneca, MSD Oncology, Pfizer, Bristol-Myers Squibb, Amgen, Rakuten. Research Funding: Kura, Bristol-Myers Squibb, Roche, Amgen, Boehringer Ingelheim, Pfizer, Demo Pharmaceutical, Pharmaten. Travel, Accommodations, Expenses: Roche, MSD Oncology, Ipsen, Bristol-Myers Squibb, Ipsen. Uncompensated relationships: AstraZeneca, AstraZeneca. Lisa Licitra: Grants/research supports (funds received by my institution for clinical studies and research activities in which I am involved): AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Debiopharm International SA, Eisai, Exelixis Inc., Hoffmann-La Roche Ltd., IRX Therapeutics Inc., Medpace Inc., Merck-Serono, MSD, Novartis, Pfizer, Roche. Honoraria or consultation fees (for public speaking/teaching in medical meetings and/or for expert opinion in advisory boards): AstraZeneca, Bayer, BMS, Eisai, MSD, Merck-Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm International SA, Sobi, Ipsen, Incyte Biosciences Italy srl, Doxa Pharma, Amgen, Nanobiotics Sa and GSK. Public speaking/teaching from research companies & commercial education providers: AccMed, Medical Science Fundation G. Lorenzini, Associazione Sinapsi, Think 2 IT, Aiom Servizi, Prime Oncology, WMA Congress Education, Fasi, DueCl promotion Srl, MI&T, Net Congress & Education, PRMA Consulting, Kura Oncology, Health & Life srl, Immun-Oncology Hub. Cristiana Bergamini and Stefano Cavalieri have no conflict of interest to disclose.

AUTHOR CONTRIBUTIONS
All authors contributed to the writing of the report and provided final approval to submit the manuscript for publication.

DATA AVAILABILITY STATEMENT
Author elects to not share data.

ORCID
Cristiana Bergamini https://orcid.org/0000-0001-7616-5125
Stefano Cavalieri https://orcid.org/0000-0003-1294-6859

REFERENCES
1. Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184.
2. Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist. 2004;9(5):561-570.
3. Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med. 2018;7(2):265-273.
4. Soria JC, Deutsch E. Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy? Ann Oncol. 2011;22(6):1247-1249.
5. Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019;19(1):151.
6. Suarez C, Fernandez-Alvarez V, Hamoir M, et al. Carotid blowout syndrome: modern trends in management. Cancer Manag Res. 2018;10:5617-5628.
7. Ernemann U, Herrmann C, Plontke S, Jasssen, Plasswilm L, Skalej M. Pseudoaneurysm of the superior thyroid artery following radiotherapy for hypopharyngeal cancer. Ann Otol Rhinol Laryngol. 2003;112(2):188-190.
8. Chen YJ, Wang CP, Wang CC, Jiang RS, Lin JC, Liu SA. Carotid blowout in patients with head and neck cancer: associated factors and treatment outcomes. Head Neck. 2015;37(2):265-272.
9. Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol Lett. 2018;15(5):7497-7505.
10. Keytruda® (pembrolizumab). Highlights of prescribing information. Whitehouse Station, NJ: Merck & Co., Inc.; 2017.
11. Opdivo® (nivolumab). Highlights of prescribing information. Princeton, NJ: Bristol-Myers Squibb Co.; 2017.
12. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311-319.
13. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733-3739.

14. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35(14):1542-1549.

15. Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838-3845.

16. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867.

17. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004-2012.

18. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.

19. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017.

20. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956-965.

21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.

22. Siu LL, Even C, Mesia R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. JAMA Oncol. 2019;5(2):195-203.

23. Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142-152.

24. Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (EAGLE): a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942-950.

25. Summary: Analyses of Truven MarketScan data for event rates of hemorrhage in head and neck cancer and all malignant neoplasms (solid tumors) (2010–2015).

26. Bleeding in recurrent and/or metastatic patients with head and neck squamous cell carcinoma: the experience at the Istituto Nazionale Tumori of Milan” (1984–2016).

27. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 22.0. March 2019. https://www.meddra.org/sites/default/files/guidance/file/smq_intguide_22_0_english.pdf. Accessed January 23, 2020.

28. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed January 20, 2020.

29. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol. 2010;17(3):37-48.

30. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-1127.

31. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171-2177.

32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.

33. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646-8654.

34. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27(11):1864-1871.

35. Argris A, Li S, Savvides P, et al. Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2019;37(34):3266-3274.

36. Elice R, Rodeghiero F. Side effects of anti-angiogenic drugs. Thromb Res. 2012;129(Suppl 1):S50-S53.

37. Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One. 2014;9(3):e89960.

38. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10(3):247-257.

39. Elser C, Siu LL, Winquist E, et al. Phase II trial of soralenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25(24):3766-3773.

40. Fury MG, Xiao H, Sherman EJ, et al. Erlotinib and cisplatin in recurrent squamous-cell carcinoma of the head and neck: results from a single-arm, phase II study in patients who failed to respond to platinum-based chemotherapy. JAMA Oncol. 2019;5(2):e190766.

41. Gilbert J, Schell MJ, Zhao X, et al. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head
and neck squamous cell carcinoma. Oral Oncol. 2015;51(4):376-382.
42. Hainsworth JD, Spigel DR, Greco FA, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J. 2011;17(5):267-272.
43. Salama JK, Haraf DJ, Stenson KM, et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011;22(10):2304-2309.
44. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008;26(10):1732-1741.
45. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol. 2010;28(20):3330-3335.
46. Yoo DS, Kirkpatrick JP, Craciunescu O, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res. 2012;18(5):1404-1414.
47. Jimeno A, Posner MR, Wirth LJ, et al. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016;122(23):3641-3649.
48. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16(15):4005-4015.
49. MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug des Devel Ther. 2009;2:105-114.
50. Moore CD, Chen I. Immunotherapy in cancer treatment: a review of checkpoint inhibitors. US Pharm. 2018;42(2):27-31.
51. Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104-1111.
52. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845-1855.
53. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
54. Tecentriq® (atezolizumab). Highlights of prescribing information. South San Francisco, CA: Genentech, Inc.; 2017.
55. Yervoy® (ipilimumab). Highlights of prescribing information. Princeton, NJ: Bristol-Myers Squibb Co.; 2015.
56. Harris DG, Noble SI. Management of terminal hemorrhage in patients with advanced cancer: a systematic literature review. J Pain Symptom Manage. 2009;38(6):913-927.

How to cite this article: Bergamini C, Ferris RL, Xie J, et al. Bleeding complications in patients with squamous cell carcinoma of the head and neck. Head & Neck. 2021;1–15. https://doi.org/10.1002/hed.26772